Brexpiprazole + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autism Spectrum Disorder (ASD)
Conditions
Irritability Associated With Autism Spectrum Disorder (ASD)
Trial Timeline
Oct 30, 2019 → Sep 9, 2022
NCT ID
NCT04174365About Brexpiprazole + Placebo
Brexpiprazole + Placebo is a phase 3 stage product being developed by Lundbeck for Irritability Associated With Autism Spectrum Disorder (ASD). The current trial status is completed. This product is registered under clinical trial identifier NCT04174365. Target conditions include Irritability Associated With Autism Spectrum Disorder (ASD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04174365 | Phase 3 | Completed |
| NCT03257865 | Phase 3 | Completed |
| NCT03259555 | Phase 3 | Completed |
| NCT01670279 | Phase 1 | Completed |
Competing Products
7 competing products in Irritability Associated With Autism Spectrum Disorder (ASD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Placebo | Bristol Myers Squibb | Approved | 84 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |
| JZP541 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 60 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 2/3 | 60 |